Unraveling the complexities of targeted therapy treatment in cancer care.
This program discussed the rationale for treatment choices in non-Hodgkin lymphoma and HER-2 positive breast cancer. The mechanisms and management of infusion, cytokine-mediated, and allergic reactions related to monoclonal antibody (MOAB) therapy were covered, as well as a summary of the mechanisms of action and toxicities of MOAB therapy in breast cancer.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods; D004815:Epidermal Growth Factor / Q000187:drug effects / Q000235:genetics; D018734:Genes, erbB-2 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009859:Oncology Nursing / Q000379:methods; D010353:Patient Education as Topic; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000235:genetics
D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A; D004815:Epidermal Growth Factor